-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Monte Rosa Therapeutics (NASDAQ:GLUE) Lifted to "Overweight" at Wells Fargo & Company
Monte Rosa Therapeutics (NASDAQ:GLUE) Lifted to "Overweight" at Wells Fargo & Company
Wells Fargo & Company upgraded shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) from an equal weight rating to an overweight rating in a research note published on Monday morning, Marketbeat reports. Wells Fargo & Company currently has $18.00 target price on the stock.
A number of other research firms have also commented on GLUE. Credit Suisse Group dropped their price target on shares of Monte Rosa Therapeutics to $12.00 in a research report on Wednesday, November 16th. UBS Group began coverage on shares of Monte Rosa Therapeutics in a research report on Thursday, October 13th. They issued a buy rating and a $22.00 price target on the stock.
Get Monte Rosa Therapeutics alerts:Monte Rosa Therapeutics Stock Down 0.6 %
Shares of GLUE opened at $7.70 on Monday. The firm's 50 day moving average price is $8.51 and its 200 day moving average price is $8.75. Monte Rosa Therapeutics has a twelve month low of $6.05 and a twelve month high of $18.16.
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.03. As a group, equities analysts forecast that Monte Rosa Therapeutics will post -2.28 earnings per share for the current fiscal year.Institutional Investors Weigh In On Monte Rosa Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of Monte Rosa Therapeutics by 24.8% in the third quarter. Bank of New York Mellon Corp now owns 87,632 shares of the company's stock worth $716,000 after acquiring an additional 17,424 shares during the last quarter. Alphabet Inc. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $11,961,000. Balyasny Asset Management LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $155,000. Jane Street Group LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $410,000. Finally, State Street Corp boosted its stake in Monte Rosa Therapeutics by 7.5% during the third quarter. State Street Corp now owns 484,571 shares of the company's stock worth $3,959,000 after buying an additional 33,707 shares in the last quarter. Institutional investors and hedge funds own 83.19% of the company's stock.
Monte Rosa Therapeutics Company Profile
(Get Rating)
Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
Featured Stories
- Get a free copy of the StockNews.com research report on Monte Rosa Therapeutics (GLUE)
- Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
- Why Is Kraft Heinz Moving Higher
- What will this mean for the Devon Energy stock price this year?
- Nio Stock, Is This The Bottom ?
- Will Trade Desk Inc Bounce Off Its Support Line?
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Wells Fargo & Company upgraded shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) from an equal weight rating to an overweight rating in a research note published on Monday morning, Marketbeat reports. Wells Fargo & Company currently has $18.00 target price on the stock.
富国银行上调了的股票 蒙特罗莎疗法(纳斯达克股票代码:GLUE — 获取评级) Marketbeat报告称,从同等权重评级到周一上午发布的研究报告中的增持评级。富国银行目前该股的目标价为18.00美元。
A number of other research firms have also commented on GLUE. Credit Suisse Group dropped their price target on shares of Monte Rosa Therapeutics to $12.00 in a research report on Wednesday, November 16th. UBS Group began coverage on shares of Monte Rosa Therapeutics in a research report on Thursday, October 13th. They issued a buy rating and a $22.00 price target on the stock.
其他一些研究公司也对GLUE发表了评论。瑞士信贷集团在11月16日星期三的一份研究报告中将Monte Rosa Therapeutics股票的目标股价下调至12.00美元。瑞银集团在10月13日星期四的一份研究报告中开始报道Monte Rosa Therapeutics的股票。他们对该股发布了买入评级和22.00美元的目标价。
Monte Rosa Therapeutics Stock Down 0.6 %
蒙特罗莎疗法股价下跌0.6%
Shares of GLUE opened at $7.70 on Monday. The firm's 50 day moving average price is $8.51 and its 200 day moving average price is $8.75. Monte Rosa Therapeutics has a twelve month low of $6.05 and a twelve month high of $18.16.
周一,GLUE的股价开盘价为7.70美元。该公司的50天移动平均线价格为8.51美元,其200天移动平均线价格为8.75美元。Monte Rosa Therapeutics创下十二个月低点6.05美元,十二个月高点为18.16美元。
Institutional Investors Weigh In On Monte Rosa Therapeutics
机构投资者对 Monte Rosa Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of Monte Rosa Therapeutics by 24.8% in the third quarter. Bank of New York Mellon Corp now owns 87,632 shares of the company's stock worth $716,000 after acquiring an additional 17,424 shares during the last quarter. Alphabet Inc. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $11,961,000. Balyasny Asset Management LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $155,000. Jane Street Group LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $410,000. Finally, State Street Corp boosted its stake in Monte Rosa Therapeutics by 7.5% during the third quarter. State Street Corp now owns 484,571 shares of the company's stock worth $3,959,000 after buying an additional 33,707 shares in the last quarter. Institutional investors and hedge funds own 83.19% of the company's stock.
一些对冲基金和其他机构投资者最近修改了该股的持有量。纽约银行梅隆公司在第三季度将其在Monte Rosa Therapeutics的股份增加了24.8%。纽约银行梅隆公司在上个季度又收购了17,424股股票后,现在拥有该公司87,632股股票,价值71.6万美元。Alphabet Inc.在第三季度收购了Monte Rosa Therapeutics的新股份,价值119.61万美元。Balyasny Asset Management LLC在第三季度收购了价值15.5万美元的新股份。简街集团有限责任公司在第三季度收购了Monte Rosa Therapeutics的新股份,价值41万美元。最后,State Street Corp在第三季度将其在Monte Rosa Therapeutics的股份增加了7.5%。State Street Corp在上个季度又购买了33,707股股票后,现在拥有该公司484,571股股票,价值3,959,000美元。机构投资者和对冲基金拥有该公司83.19%的股票。
Monte Rosa Therapeutics Company Profile
蒙特罗莎疗法公司简介
(Get Rating)
(获取评分)
Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
生物制药公司Monte Rosa Therapeutics, Inc从事新型小分子精准药物的开发,这些药物利用人体的自然机制有选择地降解与治疗相关的蛋白质。它开发了一种用于 GSPT1 的口服分子胶降解剂,一种翻译终止因子和含有 degron 的蛋白质,用于治疗 MYC 驱动的癌症。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Monte Rosa Therapeutics (GLUE)
- Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
- Why Is Kraft Heinz Moving Higher
- What will this mean for the Devon Energy stock price this year?
- Nio Stock, Is This The Bottom ?
- Will Trade Desk Inc Bounce Off Its Support Line?
- 免费获取 StockNews.com 关于 Monte Rosa Therapeutics (GLUE) 的研究报告
- 由于可能的破产消息,Bed Bath & Beyond 股票暴跌了24%
- 为什么卡夫亨氏会走高
- 这对今年的德文能源股价意味着什么?
- Nio 股票,这是底部吗?
- Trade Desk Inc 会从支撑线反弹吗?
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《蒙特罗莎疗法日报》的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Monte Rosa Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧